Valuation: Provectus Biopharmaceuticals, Inc.

Market Cap 20.97M 18.72M 17.27M 15.69M 29.43M 1.99B 29.89M 208M 81.95M 1.04B 78.72M 77.03M 3.3B P/E 2024
-10.6x
P/E 2025 -4.33x
Enterprise Value 23.7M 21.15M 19.52M 17.73M 33.26M 2.24B 33.77M 235M 92.61M 1.18B 88.96M 87.05M 3.73B EV / Sales 2024
86,451,912x
EV / Sales 2025 78,013,766x
Free-Float
92.52%
Yield 2024 *
-
Yield 2025 -
08-13 Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-07 Provectus Biopharmaceuticals, Inc. Highlights Peer-Reviewed Study Demonstrating Opposing Mechanistic Effects Of Rose Bengal Sodium At The Same Dose CI
06-25 Provectus Biopharmaceuticals, Inc. Launches Veripure Open Science Program For Medical Research Access To PV-10 CI
06-18 Provectus Biopharmaceuticals, Inc. - Shareholder/Analyst Call
05-18 Provectus Biopharmaceuticals reports oral pv-10 anti-tumor activity in preclinical bladder cancer study RE
05-18 Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity In Preclinical Bladder Cancer Study CI
05-14 Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-04 Provectus Biopharmaceuticals, Inc. Presents New Data on Rose Bengal Photodynamic Antimicrobial Therapy At Arvo 2026 CI
04-02 Provectus Biopharmaceuticals Highlights Preclinical Evidence Of PV-10-Mediated Immune Modulation In Burn Wound Healing CI
03-26 Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-25 Provectus Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt CI
11-13 Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-10-09 Provectus Biopharmaceuticals Positions Pv-10 as Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel Sting-Pathway Activation for Improving Hepatitis B Vaccine Efficacy CI

Last Transcript: Provectus Biopharmaceuticals, Inc.

1 week-0.20%
Current month-12.61%
1 month-10.89%
3 months-16.13%
6 months-6.45%
Current year-10.73%
1 week 0.05
Extreme 0.0456
0.05
1 month 0.05
Extreme 0.0456
0.06
Current year 0.04
Extreme 0.038
0.08
1 year 0.04
Extreme 0.038
0.08
3 years 0.04
Extreme 0.038
0.22
5 years 0.03
Extreme 0.034
0.22
10 years 0.01
Extreme 0.011
0.22
Manager TitleAgeSince
Chief Executive Officer 73 2024-04-15
Chief Tech/Sci/R&D Officer 62 2012-05-14
Director of Finance/CFO 59 2019-03-24
Director TitleAgeSince
Chairman 57 2017-04-02
Director/Board Member 78 2018-04-26
Chairman 73 2018-04-26
Date Insider Type Main position Quantity % Market Cap. Importance
10/10/26 Exercice

Chief Executive Officer

-22,609 0.0054%
10/3/26 Exercice

Chief Executive Officer

-13,216 0.0031%
9/18/26 Exercice

Chief Executive Officer

-13,216 0.0031%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.20%-33.20%-34.34% 20.97M
-4.10%-8.35%+38.48%+66.99% 66.22B
-0.41%+4.99%+7.61%+72.82% 55.2B
+0.74%+7.31%+12.50%+88.71% 52.79B
+0.61%+2.69%+27.75%+50.97% 45.53B
-1.08%+2.19%+21.92%+131.38% 43.94B
-3.39%-0.83%+254.27%+571.04% 41.64B
-1.67%+8.06%+14.17%+56.67% 34B
-0.84%-7.73%+25.29%-2.75% 25.84B
+1.30%+6.97%+38.37%+28.59% 23.51B
Average -0.88%+0.95%+40.72%+103.01% 38.87B
Weighted average by Cap. -1.19%+0.84%+47.54%+122.30%

Financials

2024 2025
Net sales 0.62 0.55 0.51 0.46 0.87 58.46 0.88 6.12 2.41 30.63 2.32 2.27 97.02 0.34 0.3 0.28 0.25 0.47 31.84 0.48 3.33 1.31 16.68 1.26 1.23 52.84
Net income -4.76M -4.25M -3.92M -3.56M -6.68M -451M -6.79M -47.24M -18.61M -236M -17.88M -17.49M -749M -5.43M -4.85M -4.47M -4.06M -7.62M -514M -7.74M -53.88M -21.22M -270M -20.39M -19.95M -854M
Net Debt 2.88M 2.57M 2.37M 2.15M 4.04M 273M 4.1M 28.54M 11.24M 143M 10.8M 10.57M 452M 2.73M 2.43M 2.25M 2.04M 3.83M 258M 3.89M 27.06M 10.66M 135M 10.24M 10.02M 429M
Projected Income Statement - Annual - Provectus Biopharmaceuticals, Inc.
Logo Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.
Employees
6
Date Price Change Volume
26-10-22 US$0.0499 0.00% 5,211
26-10-21 US$0.0499 0.00% 20,100
26-10-20 US$0.0499 +2.04% 2,100
26-10-19 US$0.0489 +0.39% 51,200
26-10-16 US$0.0487 -2.58% 8,028
  1. Stock Market
  2. Stocks
  3. PVCT Stock